04:38 PM EDT, 05/24/2024 (MT Newswires) -- Lantern Pharma ( LTRN ) filed a registration statement covering the potential sale of up to $150 million worth of its securities.

The prospectus covers the sale from time to time in one or more offerings of common stock, preferred stock, debt securities, warrants, subscription rights and units, the company said Friday in a regulatory filing.

Net proceeds will be used for general corporate purposes, operations purposes and to fund growth, the filing showed.